Aidoc vs Lunit (2026)
Aidoc sells acute imaging triage to hospitals. Its aiOS platform runs Aidoc's own FDA cleared algorithms, plus partner algorithms, across CT and X-ray, and pushes suspected emergencies such as stroke, pulmonary embolism and bowel obstruction to the top of the radiologist's worklist. Its newest products run on CARE, Aidoc's own foundation model: a January 2026 clearance covers 11 acute findings on chest, abdomen and pelvis CT, and a February clearance adds four more. More than 1,600 medical centers use it, including Cedars-Sinai and Yale New Haven Health. Lunit, a Seoul company listed on KOSDAQ, sells cancer screening AI. Its INSIGHT products read mammograms, breast tomosynthesis and chest X-rays, and since buying Volpara in 2024 it also sells breast density, risk, quality and patient outreach software. Its strongest evidence is ScreenTrustCAD, a prospective Swedish study of 55,581 women in which AI plus one radiologist did as well as two radiologists. Screening programs and breast imaging centers are its core buyers. The two work on different clocks. Aidoc is judged on how fast an emergency finding reaches the right doctor. Lunit is judged on catching cancers early in a mostly healthy population without recalling too many women. They overlap only on chest X-ray. A hospital trying to speed acute care across its emergency imaging fits Aidoc. A breast screening program weighing AI as a second reader fits Lunit.
- One January 2026 clearance (K252970) covers 11 acute findings on chest, abdomen and pelvis CT, from appendicitis to pelvic fracture.
- Its FDA test across six US sites reported sensitivity of 94.0 to 99.3 percent and specificity of 95.7 to 99.3 percent on 1,769 scans.
- aiOS also runs partner algorithms and adds care coordination that alerts specialists for stroke, pulmonary embolism and aortic disease.
- Its security documentation describes stripping identifiers before studies leave the hospital, with separate cloud storage for each customer.
- FDA's register lists 35 Aidoc clearances, and more than 1,600 medical centers use it.
- In ScreenTrustCAD, AI plus one radiologist was noninferior to two radiologists across 55,581 screened women.
- An Emory evaluation of INSIGHT DBT across 163,449 exams found no significant difference in performance by race, ethnicity or age.
- Its breast platform adds density, risk, mammography quality and patient outreach products from the former Volpara business.
- Lunit says customer images are kept only for processing and never used to retrain its models.
- INSIGHT MMG is FDA cleared as a second look after the radiologist's own read.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aidoc and Lunit are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Aidoc
-
Regulatory / FDA
Aidoc received FDA Breakthrough Device Designation for CARE Chest X-Ray Triage, built on its CARE foundation model, covering triage of pneumomediastinum and lobar or lung collapse.
Source -
Clinical evidence
Mercy and Aidoc released a white paper, commissioned by AVIA, reporting on five months of AI deployment across the Mercy health system.
Source -
Regulatory / FDA
The FDA cleared Aidoc's comprehensive abdomen CT triage solution, powered by its self developed CARE foundation model, bringing 11 newly cleared indications together with three previously cleared into a single 14 indication workflow.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Aidoc sells acute imaging triage to health systems through aiOS, a platform running its own FDA cleared algorithms alongside partner algorithms, with care coordination that alerts specialists when a stroke, pulmonary embolism or aortic emergency is flagged. Its newest products run on CARE, its own foundation model, and the January 2026 CT body clearance covers 11 acute findings with sensitivity of 94 to 99 percent in a six site retrospective test. More than 1,600 medical centers use it. It states no business associate position, has published no study of the CT body product in clinical use, and publishes no price.
Source: AI Health Index, October 2026
Lunit, listed on KOSDAQ and based in Seoul, sells cancer screening AI: INSIGHT for mammography, breast tomosynthesis and chest X-ray, plus breast density, risk, quality and outreach software from its 2024 Volpara acquisition. Its evidence includes a prospective Swedish screening study of 55,581 women, where AI plus one radiologist matched two radiologists, and an Emory study showing tomosynthesis performance held across race, ethnicity and age. In the US its mammography AI is cleared as a second look after the radiologist's read. Lunit publishes no business associate position, hosting details or price.
Source: AI Health Index, October 2026
Questions buyers ask
How does Aidoc compare to Lunit?
Aidoc and Lunit both sell imaging AI to hospitals, for different jobs. Aidoc triages acute findings such as stroke, pulmonary embolism and bowel obstruction on CT and X-ray through its aiOS platform, and alerts the right specialists. Lunit detects cancer on mammograms, breast tomosynthesis and chest X-rays, and sells breast density, risk and outreach software around it. Emergency imaging is Aidoc's ground, and breast screening is Lunit's. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
How much do Aidoc and Lunit cost?
Neither Aidoc nor Lunit publishes a price. Aidoc sells aiOS and its modules through enterprise agreements and an AWS Marketplace listing whose price depends on the contract. Lunit sells direct and through imaging equipment partners, and offers SecondRead AI, an extra read at screening that patients pay for, without publishing what it costs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
Are Aidoc and Lunit FDA cleared?
Both hold FDA clearances. FDA's register lists 35 for Aidoc, mostly BriefCase triage devices, including K252970 in January 2026 for 11 acute findings on body CT and K253578 in February 2026 for four more. Lunit's INSIGHT MMG was cleared in 2021 (K211678) as an adjunct read after the radiologist's own, INSIGHT CXR Triage in 2021 and INSIGHT DBT in 2023. Aidoc's and Lunit's cleared products triage or support a read rather than diagnose on their own. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
What evidence supports Aidoc and Lunit?
Lunit's ScreenTrustCAD study (The Lancet Digital Health, 2023) prospectively tested INSIGHT MMG on 55,581 women in Stockholm and found AI plus one radiologist noninferior to two radiologists. Aidoc's evidence for its CT body product is its own retrospective FDA test on 1,769 scans across six US sites, with sensitivity of 94.0 to 99.3 percent and a mean of 45 seconds to notification.
Aidoc reports faster pulmonary embolism notification and stroke treatment on its home page without naming the studies. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
How do Aidoc and Lunit handle patient data and security?
Aidoc and Lunit both claim ISO 27001 certification and run trust centers. Aidoc's documentation describes stripping identifiers before studies leave the hospital and giving each customer separate cloud storage on AWS and Azure. Lunit says images are kept only for processing and never used to retrain its models, but does not say where processing happens. Neither states business associate status in its public documents. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Aidoc is based in Tel Aviv and was founded in 2016. Lunit is based in Seoul and listed on KOSDAQ, and its density, risk and outreach products came from Volpara Health, acquired in 2024. Neither publishes a price or business associate terms. Aidoc publishes no accuracy results by patient group, does not say whether customer studies help train CARE, and its detailed security document dates from 2020. Lunit publishes group results for tomosynthesis but not for mammography or chest X-ray. In Sweden its mammography AI was tested as a replacement for one of two readers, a role outside its US clearance.